John H. Baird, M.D., was drawn to his career as a doctor when he found working with patients to be his favorite part of his initial focus in biomedical engineering. For him, being a physician-researcher is the best of both worlds. He provides innovative therapies and his own brand of compassionate care to people with leukemia and lymphoma, while also advancing the state of the field in cancer treatment and improving patient outcomes with clinical research.
Dr. Baird pursued his medical training at the University of Arkansas, then served as an intern and resident at the University of Pennsylvania and a fellow at Stanford University, where he specialized in medical oncology, hematology, and blood and marrow transplantation. His research concerns next-generation cellular therapies for blood diseases, including CAR T cell therapy, in which a patient's own immune cells are engineered to seek and destroy cancer.
American Society for Transplantation and Cellular Therapy
American Society of Hematology, Associate Member
American Society of Clinical Oncology
CIBMTR Infection and Immune Reconstitution Working Group
American College of Physicians
Baird JH, Frank MJ, Craig J, et al.: “CD22-directed CAR T-cell therapy induces complete remissions in CD19-directed CAR-refractory large B-cell lymphoma.” Blood. 2021; doi: 10.1182/blood.2020009432.
Spiegel JY, Patel S, Muffly L, Hossain N, Oak J, Baird JH, et al.: “Dual targeting CD19/CD22 chimeric antigen receptor T cells in adults with recurrent or refractory B cell malignancies.” Nat Med. 2020 in submission.
Johnsrud AJ, Craig J, Baird JH, et al. “Incidence and risk factors associated with bleeding and thrombosis following chimeric antigen receptor T cell therapy.” Blood Adv. 2021; doi: 10.1182/bloodadvances.2021004716.
Baird JH, Epstein DJ, Tamaresis JS, et al.: “Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma.” Blood Adv. 2021; 5(1):143-55.
Van Vuren AJ, Minniti CP, Mendelsohn L, Baird JH, et al.: “Lactate dehydrogenase to carboxyhemoglobin ratio as a biomarker of heme release to heme processing is associated with higher tricuspid regurgitant jet velocity and early death in SCD.” Am J
Baird JH, Gotlib J, George TI, et al.: “A phase 2 study of brentuximab vedotin in patients with CD30-positive advanced systemic mastocytosis.” Blood Adv. 2019 Aug 13;3(15):2264-2271.
Baird JH, Gotlib J: “Clinical validation of KIT inhibition in advanced systemic mastocytosis.” Curr Hematol Malig Rep. 2018 Oct;13(5):407-416.
Baird JH, Minniti CP, Lee JM, Tian X, et al.: “Oscillatory haematopoiesis in adults with sickle cell disease treated with hydroxycarbamide.” Br. J. Haematol. 2015; 168(5):737-46. 7.
Baird JH, Frey N, Birnbaum B, Porter DL: “Voriconazole-induced periostitis after allogeneic stem cell transplantation.” Am. J. Hematol. 2015; 90(6):574-5.
Lodhi IJ, Yin L, Coleman T, Baird JH, et al.: “Targeted inhibition of adipose lipogenesis decreases obesity and insulin resistance by disrupting PPAR-γ activation.” Cell Metab. 2012; 16(2):189-201.